MX2021000011A - Derivados fosfonato y fosfato de 7-amino-5-tio-tiazol[4,5-d]pirimi dinas y su uso en el tratamiento de afecciones asociadas con niveles elevados de cx3cr1 y/o cx3cl1. - Google Patents
Derivados fosfonato y fosfato de 7-amino-5-tio-tiazol[4,5-d]pirimi dinas y su uso en el tratamiento de afecciones asociadas con niveles elevados de cx3cr1 y/o cx3cl1.Info
- Publication number
- MX2021000011A MX2021000011A MX2021000011A MX2021000011A MX2021000011A MX 2021000011 A MX2021000011 A MX 2021000011A MX 2021000011 A MX2021000011 A MX 2021000011A MX 2021000011 A MX2021000011 A MX 2021000011A MX 2021000011 A MX2021000011 A MX 2021000011A
- Authority
- MX
- Mexico
- Prior art keywords
- diseases
- sup
- cx3cl1
- cx3cr1
- elevated levels
- Prior art date
Links
- 229910019142 PO4 Inorganic materials 0.000 title 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 title 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title 1
- 239000010452 phosphate Substances 0.000 title 1
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000020084 Bone disease Diseases 0.000 abstract 1
- 208000014644 Brain disease Diseases 0.000 abstract 1
- 108090000835 CX3C Chemokine Receptor 1 Proteins 0.000 abstract 1
- 102100039196 CX3C chemokine receptor 1 Human genes 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 102100020997 Fractalkine Human genes 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 abstract 1
- 241000725303 Human immunodeficiency virus Species 0.000 abstract 1
- 208000012659 Joint disease Diseases 0.000 abstract 1
- 208000019693 Lung disease Diseases 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000038016 acute inflammation Diseases 0.000 abstract 1
- 230000006022 acute inflammation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037976 chronic inflammation Diseases 0.000 abstract 1
- 230000006020 chronic inflammation Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000030533 eye disease Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporciona un compuesto de fórmula I (ver fórmula), en donde R1, R2, Q1 y la fórmula (X) (ver fórmula) son como se definen en la presente descripción, cuyos compuestos son útiles en el tratamiento de enfermedades y trastornos asociados con niveles elevados de CX3CR1 y/o CX3CL1, en particular inflamación aguda y/o crónica, enfermedades oculares, enfermedades pulmonares, enfermedades de la piel, enfermedades de las articulaciones y/o huesos, enfermedades autoinmunitarias, enfermedades cardiovasculares, enfermedades metabólicas, enfermedades cerebrales, enfermedades neurodegenerativas, dolor, cáncer, enfermedades hepáticas, enfermedades renales, enfermedades gastrointestinales, virus de inmunodeficiencia humana y trastornos del estado de ánimo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1811169.0A GB201811169D0 (en) | 2018-07-06 | 2018-07-06 | New compounds |
| PCT/EP2019/068169 WO2020008064A1 (en) | 2018-07-06 | 2019-07-05 | Phosphate and phosphonate derivatives of 7-amino-5-thio-thiazolo[4,5-d]pyrimidines and their use in treating conditions associated with elevated levels of cx3cr1 and/or cx3cl1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021000011A true MX2021000011A (es) | 2021-05-12 |
Family
ID=63273083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000011A MX2021000011A (es) | 2018-07-06 | 2019-07-05 | Derivados fosfonato y fosfato de 7-amino-5-tio-tiazol[4,5-d]pirimi dinas y su uso en el tratamiento de afecciones asociadas con niveles elevados de cx3cr1 y/o cx3cl1. |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20210292349A1 (es) |
| EP (1) | EP3818065B1 (es) |
| JP (1) | JP2021530474A (es) |
| KR (1) | KR20210032403A (es) |
| CN (1) | CN112867725A (es) |
| AU (1) | AU2019297572A1 (es) |
| CA (1) | CA3105566A1 (es) |
| CY (1) | CY1126070T1 (es) |
| DK (1) | DK3818065T3 (es) |
| ES (1) | ES2945561T3 (es) |
| FI (1) | FI3818065T3 (es) |
| GB (1) | GB201811169D0 (es) |
| HR (1) | HRP20230532T1 (es) |
| HU (1) | HUE062011T2 (es) |
| IL (1) | IL279818B1 (es) |
| LT (1) | LT3818065T (es) |
| MX (1) | MX2021000011A (es) |
| PL (1) | PL3818065T3 (es) |
| PT (1) | PT3818065T (es) |
| SG (1) | SG11202100014RA (es) |
| SI (1) | SI3818065T1 (es) |
| WO (1) | WO2020008064A1 (es) |
| ZA (1) | ZA202100192B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
| GB202006849D0 (en) | 2020-05-08 | 2020-06-24 | Kancera Ab | New use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0101082D0 (sv) * | 2001-03-27 | 2001-03-27 | Astrazeneca Ab | Novel use |
| CA2525245C (en) * | 2003-06-27 | 2010-10-19 | Pfizer Products Inc. | Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| MXPA06003792A (es) | 2003-10-07 | 2006-06-14 | Astrazeneca Ab | Nuevas 4-amino-tiazolo[4,5-d]-pirimidinas 2-sustituidas, utiles como antagonistas del receptor de quimiocina, especialmente cx3cr1. |
| WO2006048754A1 (en) * | 2004-11-02 | 2006-05-11 | Pfizer Japan Inc. | Sulfonyl benzimidazole derivatives |
| UA90707C2 (en) | 2005-04-06 | 2010-05-25 | Астразенека Аб | Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives |
| AR053347A1 (es) * | 2005-04-06 | 2007-05-02 | Astrazeneca Ab | Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos |
| WO2008005555A1 (en) | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| CN101522693B (zh) * | 2006-09-29 | 2012-01-04 | 阿斯利康(瑞典)有限公司 | 5，7-二取代的[1，3]噻唑并[4，5-d]嘧啶-2(3h)-胺衍生物和它们在治疗中的用途 |
| TW200820973A (en) * | 2006-09-29 | 2008-05-16 | Astrazeneca Ab | Novel compounds 480 |
| CN101516893B (zh) * | 2006-09-29 | 2011-11-30 | 阿斯利康(瑞典)有限公司 | 5,7-二取代的[1,3]噻唑并[4,5-d]嘧啶-2(3h)-酮衍生物和它们在治疗中的用途 |
| PE20091102A1 (es) * | 2007-12-17 | 2009-07-25 | Janssen Pharmaceutica Nv | Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1 |
| AR071036A1 (es) * | 2008-03-26 | 2010-05-19 | Astrazeneca Ab | Derivados 5, 7-disustituidos de [1, 3]tiazolo[4, 5-d]pirimidin-2 (3h)-ona, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor cx3cr1. |
| EP2563366A4 (en) * | 2010-04-30 | 2013-11-20 | Univ California | USE OF PHOSPHOLIPID CONJUGATES FROM SYNTHETIC TLR7 AGONISTS |
| CN104640444B (zh) * | 2012-06-16 | 2016-12-14 | 河南美泰宝生物制药有限公司 | 双肝脏靶向氨基磷酸酯和氨基膦酸酯前药 |
| WO2016200939A1 (en) | 2015-06-08 | 2016-12-15 | The Johns Hopkins University | Radiofluorinated 7-amino-5-thio-thiazolo[4,5-d]pyrimidines for imaging fractalkine receptor (cx3cr1) |
| GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
-
2018
- 2018-07-06 GB GBGB1811169.0A patent/GB201811169D0/en not_active Ceased
-
2019
- 2019-07-05 MX MX2021000011A patent/MX2021000011A/es unknown
- 2019-07-05 EP EP19739234.3A patent/EP3818065B1/en active Active
- 2019-07-05 PT PT197392343T patent/PT3818065T/pt unknown
- 2019-07-05 CA CA3105566A patent/CA3105566A1/en active Pending
- 2019-07-05 FI FIEP19739234.3T patent/FI3818065T3/fi active
- 2019-07-05 PL PL19739234.3T patent/PL3818065T3/pl unknown
- 2019-07-05 LT LTEPPCT/EP2019/068169T patent/LT3818065T/lt unknown
- 2019-07-05 DK DK19739234.3T patent/DK3818065T3/da active
- 2019-07-05 HU HUE19739234A patent/HUE062011T2/hu unknown
- 2019-07-05 CN CN201980057603.6A patent/CN112867725A/zh active Pending
- 2019-07-05 AU AU2019297572A patent/AU2019297572A1/en active Pending
- 2019-07-05 US US17/257,917 patent/US20210292349A1/en active Pending
- 2019-07-05 HR HRP20230532TT patent/HRP20230532T1/hr unknown
- 2019-07-05 JP JP2021500175A patent/JP2021530474A/ja active Pending
- 2019-07-05 IL IL279818A patent/IL279818B1/en unknown
- 2019-07-05 KR KR1020217003104A patent/KR20210032403A/ko not_active Application Discontinuation
- 2019-07-05 WO PCT/EP2019/068169 patent/WO2020008064A1/en unknown
- 2019-07-05 SG SG11202100014RA patent/SG11202100014RA/en unknown
- 2019-07-05 ES ES19739234T patent/ES2945561T3/es active Active
- 2019-07-05 SI SI201930537T patent/SI3818065T1/sl unknown
-
2021
- 2021-01-12 ZA ZA2021/00192A patent/ZA202100192B/en unknown
- 2021-07-09 US US17/372,125 patent/US11339183B2/en active Active
-
2023
- 2023-06-15 CY CY20231100281T patent/CY1126070T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SI3818065T1 (sl) | 2023-08-31 |
| PT3818065T (pt) | 2023-05-30 |
| DK3818065T3 (da) | 2023-05-15 |
| FI3818065T3 (fi) | 2023-06-13 |
| ES2945561T3 (es) | 2023-07-04 |
| GB201811169D0 (en) | 2018-08-29 |
| KR20210032403A (ko) | 2021-03-24 |
| HUE062011T2 (hu) | 2023-09-28 |
| ZA202100192B (en) | 2023-07-26 |
| CA3105566A1 (en) | 2020-01-09 |
| WO2020008064A1 (en) | 2020-01-09 |
| JP2021530474A (ja) | 2021-11-11 |
| US20210292349A1 (en) | 2021-09-23 |
| HRP20230532T1 (hr) | 2023-08-04 |
| IL279818B1 (en) | 2024-02-01 |
| CY1126070T1 (el) | 2023-11-15 |
| IL279818A (en) | 2021-03-01 |
| US11339183B2 (en) | 2022-05-24 |
| LT3818065T (lt) | 2023-06-26 |
| EP3818065A1 (en) | 2021-05-12 |
| US20210340167A1 (en) | 2021-11-04 |
| CN112867725A (zh) | 2021-05-28 |
| SG11202100014RA (en) | 2021-01-28 |
| AU2019297572A1 (en) | 2021-01-28 |
| EP3818065B1 (en) | 2023-03-15 |
| PL3818065T3 (pl) | 2023-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020500265A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| PH12020551043A1 (en) | Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues | |
| CY1126070T1 (el) | Φωσφορικα και φωσφονικα παραγωγα των 7-αμινο-5-θειο-θειαζολο[4,5-d]πυριμιδινων και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων που σχετιζονται με αυξημενα επιπεδα toy cx3cr1 και/ή toy cx3cl1 | |
| EA202191050A1 (ru) | Ингибиторы pfkfb3 и их использование | |
| EA202092154A1 (ru) | Комбинированная терапия | |
| PT1448564E (pt) | Composto do tipo indolizina substituidos e metodos de utilizacao | |
| WO2006058868A3 (de) | Substituierte pteridine zur behandlung von entzündlichen erkrankungen | |
| PH12016501651A1 (en) | Triazine compound and use thereof for medical purposes | |
| TN2017000158A1 (en) | Carbazole derivatives | |
| DK3906066T3 (da) | Geneterapikonstruktioner til behandling af wilsons sygdom | |
| EA201592287A1 (ru) | Замещенные тетрагидрокарбазольные и карбазолкарбоксамидные соединения | |
| AU2018264384A1 (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
| PH12020550452A1 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (pf-ild) | |
| MX2020008680A (es) | Terapia de combinacion con apilimod y agentes glutamatergicos. | |
| DK3749308T3 (da) | Behandling af patienter med klassisk fabrys sygdom med migalastat | |
| EA202092459A1 (ru) | Гибридные белки интерлейкина 12, композиции и способы терапевтического применения, которые их включают | |
| MX2018002932A (es) | Sintesis y composicion de agentes terapeuticos fotodinamicos para el tratamiento dirigido del cancer. | |
| WO2018154118A3 (en) | Aromatic compounds which enhance notch signaling, for use in therapy | |
| MX2019006141A (es) | Metodos para tratar trastornos inflamatorios con compuestos de fc multivalentes. | |
| MX2019004200A (es) | Terapia de combinacion. | |
| EP4324522A3 (en) | Methods of treating fabry patients having renal impairment | |
| EA201992869A1 (ru) | Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность | |
| EA202091647A1 (ru) | Соединения, композиции и способы лечения заболеваний, связанных с ацидозными или гипоксическими пораженными тканями | |
| EA202190787A1 (ru) | Пиридазиноны и способы их применения | |
| EA202192582A1 (ru) | Соединения и их применение |